Combined treatment with minodronate and vitamin C increases bone mineral density and strength in vitamin C-deficient rats

다국어 초록 (Multilingual Abstract)

Objectives: Reduced bone quality caused by vitamin C deficiency in older persons may lead to incidental fragility fractures during bisphosphonate treatment, although bisphosphonate increases bone mineral density (BMD). This study aimed to evaluate the effects of minodronate and ascorbic acid (Aa) on BMD, bone quality, and bone strength in Aa-deficient osteogenic disorder Shionogi (ODS) rats.

Methods: Six-month-old ODS rats were divided into four groups (n ¼ 20 per group): (1) Aa supplementation (Aa þ ); (2) Aa-deficient (Aa ? ); (3) Aa supplementation and minodronate administration (Aaþ þ Mino); and (4) Aa-deficient and minodronate administration (Aa? þ Mino). BMD, bone strength, bone histomorphometry, and bone quality determined using Fourier transform infrared spectroscopy imaging (FTIRI) were evaluated after 4 and 8 weeks.

Results: BMD was significantly higher in the Aaþ þ Mino group than in the Aa? group ( p < 0.05). Bone strength was significantly higher in the Aaþ and Aaþ þ Mino groups than in the Aa? group ( p < 0.05). Furthermore, bone strength was significantly higher in the Aaþ þ Mino group than in the Aa? þ Mino group ( p < 0.05). Minodronate treatment irrespective of Aa supplementation significantly decreased bone resorption compared with the Aaþ and Aa? groups ( p < 0.05). No significant differences in the parameters evaluated by FTIRI were observed between the groups.

Conclusions: Aa supplementation improved bone strength in ODS rats. Combined treatment with minodronate and Aa, but not minodronate alone, improved bone strength and increased BMD. Aa is required for bone health because it is essential for osteoblast differentiation.

© 2016 The Korean Society of Osteoporosis. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

참고문헌 (Reference)

1 Richardson T, "Will an orange a day keep the doctor away?" 78 : 291-294, 2002

2 Konishi T, "What is the ODS rat? historical description of the characterization studies: vitamin C and the scurvyprone ODS rat" 49 : 3-22, 1990

3 Martínez-Ramírez MJ, "Vitamin C, vitamin B12, folate and the risk of osteoporotic fractures. A case control study" 277 : 359-368, 2007

4 Krane SM, "Urinary polypeptides related to collagen synthesis" 49 : 716-729, 1970

5 Guyatt GH, "Summary of meta-analyses of therapies for postmenopausal osteoporosis and the relationship between bone density and fractures" 31 : 659-679, 2002

6 Dunford J, "Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogencontaining bisphosphonates" 296 : 235-242, 2001

7 Nakajima A, "Spatial and temporal gene expression for fibroblast growth factor type I receptor (FGFR1) during fracture healing in the rat" 29 : 458-466, 2001

8 Oeffinger KC, "Scurvy: more than historical relevance" 48 : 609-613, 1993

9 Harada S, "Role of ascorbic acid in the regulation of proliferation in osteoblast like MC3T3-E1 cells" 9 : 903-908, 1991

10 Horio F, "Requirement for ascorbic acid in a rat mutant unable to synthesize ascorbic acid" 115 : 1630-1640, 1985

11 Reginster J, "Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral efficacy with risedronate therapy (VERT) study group" 11 : 83-91, 2000

12 Allison GG, "Quantification of hydroxycinnamic acids and lignin in perennial forage and energy grasses by Fourier-transform infrared spectroscopy and partial least squares regression" 100 : 1252-1261, 2009

13 Makino S, "Osteogenic disorder rat" 29 : 374-375, 1980

14 Hagino H, "Number and severity of prevalent vertebral fractures and the risk of subsequent vertebral fractures in Japanese women with osteoporosis:results from the minodronate trial" 31 : 544-550, 2013

15 Xing W, "Nuclear factor-E2-related factor-1 mediates ascorbic acid induction of osterix expression via interaction with antioxidant-responsive element in bone cells" 282 : 22052-22061, 2007

16 Sakamoto Y, "Morphological influence of ascorbic acid deficiency on endochondral ossification in osteogenic disorder Shionogi rat" 268 : 93-104, 2002

17 Hasegawa T, "Morphological assessment of bone mineralization in tibial metaphyses of ascorbic acid-deficient ODS rats" 32 : 259-269, 2011

18 Mori H, "Minodronic acid (ONO-5920/YM529) prevents decrease in bone mineral density and bone strength, and improves bone microarchitecture in ovariectomized cynomolgus monkeys" 243 : 840-848, 2008

19 Cranney A, "Meta-analyses of therapies for postmenopausal osteoporosis. VI. Metaanalysis of calcitonin for the treatment of postmenopausal osteoporosis" 23 : 540-551, 2002

20 Falch J, "Low levels of serum ascorbic acid in elderly patients with hip fracture" 58 : 225-228, 1998

21 Tamura Y, "Longterm effects of withdrawal of bisphosphonate incadronate disodium (YM175) on bone mineral density, mass, structure, and turnover in the lumbar vertebrae of ovariectomized rats" 16 : 541-549, 2001

22 Sudo H, "In vitro differentiation and calcification in a new clonal osteogenic cell line derived from newborn mouse calvaria" 96 : 191-198, 1983

23 Murata A, "Impaired vitamin C status of hospitalized elderly patients and its improvement by daily multivitamin supplementation" 69 : 85-92, 1995

24 Cranney A, "Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data" 20 : 291-297, 2009

25 Suzawa M, "Extracellular matrix associated bone morphogenetic proteins are essential for differentiation of murine osteoblastic cells in vitro" 140 : 2125-2133, 1999

26 Mori H, "Efficacy of preventive and therapeutic treatments with minodronic acid on ovariectomized rat model of osteoporosis" 18 : 33-48, 2008

27 Harris ST, "Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral efficacy with risedronate therapy (VERT) study group" 14 : 1344-1352, 1999

28 Sugimoto T, "Effects of ascorbic acid on alkaline phosphatase activity and hormone responsiveness in the osteoblastic osteosarcoma cell line UMR-106" 39 : 171-174, 1986

29 Alcantara-Martos T, "Effect of vitamin C on fracture healing in elderly Osteogenic Disorder Shionogi rats" 89 : 402-407, 2007

30 Suzuki K, "Effect of combined treatment of insulin and human parathyroid hormone (1-34)on cancellous bone mass and structure in streptozotocin-induced diabetic rats" 33 : 108-114, 2003

31 Paschalis EP, "Distribution of collagen cross-links in normal human trabecular bone" 18 : 1942-1946, 2003

32 Takeuchi Y, "Differentiation and cell surface expression of transforming growth factor-beta receptors are regulated by interaction with matrix collagen in murine osteoblastic cells" 271 : 3938-3944, 1996

33 Nojiri H, "Cytoplasmic superoxide causes bone fragility owing to low-turnover osteoporosis and impaired collagen cross-linking" 26 : 2682-2694, 2011

34 Hara K, "Collagen-rerated abnormalities, reduction in bone quality, and effects of menatetrenone in rats with a congenital ascorbic acid deficiency" 27 : 324-332, 2009

35 Paschalis P, "Bone mineral and collagen quality in iliac crest biopsies of patients given teriparatide: new results from the fracture prevention trial" 90 : 4644-4649, 2005

36 Parfitt AM, "Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR histomorphometry nomenclature committee" 2 : 595-610, 1987

37 Tsunenari T, "Bone histomorphometric analysis for the cause of osteopenia in vitamin-deficient rat (ODS rat)" 48 : 18-27, 1991

38 Lin JH, "Bisphosphonates: a review of their pharmacokinetic properties" 18 : 75-85, 1996

39 Gourion-Arsiquaud S, "Bisphosphonate treatment modifies canine bone mineral density and matrix properties and their heterogeneity" 46 : 666-672, 2010

40 Peterkofsky B, "Ascorbate requirement for hydroxylation and secretion of procollagen: relationship to inhibition of collagen synthesis in scurvy" 54 : 1135-1140, 1991

41 Paschalis EP, "-induced alterations in collagen cross-links influence the mechanical properties of bone material without affecting the mineral" 49 : 1232-1241, 2011